Skip to contentN
Northwest Biotherapeutics Inc
N
NWBONorthwest Biotherapeutics Inc Q2 2023 · 10-Q
Revenue$201.00K$201.00K−57.9% vs Q2 2022 Net Income-$14.45M-$14.45MN/M vs Q2 2022 EPS Diluted-$0.01-$0.01N/M vs Q2 2022 Operating Income-$13,577,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Northwest Biotherapeutics Inc · CIK 1072379 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6754.7%−2331.5 pt vs Q2 2022
Net margin-7188.1%−968.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 9, 2023 · 40 d after period end